ITOS Projected Dividend Yield
iTeos Therapeutics Inc ( NASDAQ : ITOS )iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. 20 YEAR PERFORMANCE RESULTS |
ITOS Dividend History Detail ITOS Dividend News ITOS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |